85 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
1597853	2	A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1.	National Cancer Institute-Frederick
1992155	30	Design of potent protein kinase inhibitors using the bisubstrate approach.	Ura Cnrs 1309
2342075	11	Synthesis of quaternary amine ether lipids and evaluation of neoplastic cell growth inhibitory properties.	University Of North Carolina
11454465	4	Synthesis of N-alkyl substituted indolocarbazoles as potent inhibitors of human cytomegalovirus replication.	Glaxosmithkline
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School Of Medicine At Mount Sinai
25000588	72	Discovery of selective and orally bioavailable protein kinase C¿ (PKC¿) inhibitors from a fragment hit.	Abbvie Bioresearch Center
23394126	170	Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).	Exelixis
23398373	88	Design and optimization of selective protein kinase C¿ (PKC¿) inhibitors for the treatment of autoimmune diseases.	Vertex Pharmaceuticals
23039927	44	Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases.	Martin-Luther-University Halle-Wittenberg
22625994	28	Structure-activity studies on the spiroketal moiety of a simplified analogue of debromoaplysiatoxin with antiproliferative activity.	Kyoto University
9677190	49	Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.	University Of California
18077363	314	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.	University Of Oxford
17977729	40	Design and physicochemical properties of new fluorescent ligands of protein kinase C isozymes focused on CH/pi interaction.	Kyoto University
17935989	146	Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.	Abbott Laboratories
16876403	85	Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.	Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
12672248	50	Kinase inhibitors: not just for kinases anymore.	Northwestern University
12954055	47	Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.	Johnson And Johnson Pharmaceutical Research And Development
12166950	208	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.	Millennium Pharmaceuticals
8289196	7	New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C.	University Of North Carolina
10999477	40	Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.	Kyoto University
10843211	38	Structure-activity relationship studies of flavopiridol analogues.	Mitotix
	80	Synthesis and PKC inhibitory activities of balanol analogs with a cyclopentane substructure	TBA
22014550	337	Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).	Ansaris
21696964	12	Generation of 'Unnatural Natural Product' library and identification of a small molecule inhibitor of XIAP.	Keio University
21548579	4	Hippolides A-H, acyclic manoalide derivatives from the marine sponge Hippospongia lachne.	Second Military Medical University
21035334	55	Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors.	Martin-Luther-University Halle-Wittenberg
20817520	40	Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity.	Kyoto University
20346655	117	Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.	Abbott Laboratories
19926477	100	2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.	Abbott Laboratories
8176401	21	Anti-AIDS Agents, 11. Betulinic Acid and Platanic Acid as Anti-HIV Principles from Syzigium claviflorum, and the Anti-HIV Activity of Structurally Related Triterpenoids	TBA
	4	Benzo[c]quinoliziniums: A new family of inhibitors for protein kinase CK II	TBA
	42	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation	TBA
	77	Synthesis and protein kinase C inhibitory activities of indane analogs of balanol	TBA
	70	Potent and selective PKC inhibitory 5-membered ring analogs of balanol with replacement of the carboxamide moiety	TBA
	40	Heteroatom effect in the PKC inhibitory activities of perhydroazepine analogs of balanol	TBA
	88	Novel PKC inhibitory analogs of balanol with replacement of the ester functionality	TBA
	7	Conformationally constrained analogues of diacylglycerol (DAG). 4. Interaction of α-alkylidene-γ-lactones with protein kinase C (PK-C)	TBA
19379015	40	Conformationally constrained analogues of diacylglycerol (DAG). 31. Modulation of the biological properties of diacylgycerol lactones (DAG-lactones) containing rigid-rod acyl groups separated from the core lactone by spacer units of different lengths.	National Cancer Institute-Frederick
19109017	4	(-)-Cercosporamide derivatives as novel antihyperglycemic agents.	Daiichi Sankyo
17875639	12	Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.	University Of California San Francisco
18072722	42	Synthesis, conformational analysis, and biological evaluation of 1-hexylindolactam-V10 as a selective activator for novel protein kinase C isozymes.	Kyoto University
17658776	109	Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.	Abbott Laboratories
17287122	79	Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors.	Abbott Laboratories
16682193	62	Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16640328	13	Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta.	Kyoto University
16216497	67	Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.	Abbott Bioresearch Center
15771419	134	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.	Johnson & Johnson Pharmaceutical Research & Development
15317463	16	Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity.	Bristol-Myers Squibb Pharmaceutical Research Institute
15149684	59	3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3.	Johnson & Johnson Pharmaceutical Research & Development
14552791	35	Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.	Eli Lilly
12954072	46	New bivalent PKC ligands linked by a carbon spacer: enhancement in binding affinity.	Georgetown University Medical Center
12941331	96	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.	Johnson & Johnson Pharmaceutical Research & Development
12941324	66	Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.	Kyoto University
12824047	99	Novel IKK inhibitors: beta-carbolines.	Millennium Pharmaceuticals
12749884	126	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.	Eli Lilly
12672234	64	Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.	Boehringer Ingelheim Pharmaceuticals
12270156	8	Synthesis and kinase inhibitory activity of 3'-(S)-epi-K-252a.	Cephalon
12039590	51	Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck.	Abbott Bioresearch Center
11909733	30	Beta-carbolines as specific inhibitors of cyclin-dependent kinases.	Institute Of Molecular And Cell Biology
11327599	25	Rational design, synthesis, and biological evaluation of rigid pyrrolidone analogues as potential inhibitors of prostate cancer cell growth.	Georgetotwn University
11266178	39	The amide hydrogen of (-)-indolactam-V and benzolactam-V8's plays a critical role in protein kinase C binding and tumor-promoting activities.	Kyoto University
11266177	26	The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.	Kyoto University
11012021	69	Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I.	Basf Bioresearch
10743939	63	Synthesis and biological activities of NB-506 analogues modified at the glucose group.	Banyu Tsukuba Research Institute
10612598	29	4-Pyridin-5-yl-2-(3,4,5-trimethoxyphenylamino)pyrimidines: potent and selective inhibitors of ZAP 70.	Celltech Therapeutics
10612590	56	Synthesis and biological activities of NB-506 analogues: Effects of the positions of two hydroxyl groups at the indole rings.	Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
10397502	36	Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes.	Stanford University
9135029	29	Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivity.	Georgetown University Medical Center
9003521	249	Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety.	Eli Lilly
8709095	87	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.	Eli Lilly
11451670	11	Hexosaminidase inhibitors as new drug candidates for the therapy of osteoarthritis.	The Scripps Research Institute
15689148	19	Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors.	Shanghai Institute Of Materia Medica
15664516	21	Specificity and affinity of natural product cyclopentapeptide inhibitors against A. fumigatus, human, and bacterial chitinases.	University Of Dundee
15026054	55	Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum.	Cnrs